CN102686222B - 包含mgbg的口服递送药物以及治疗疾病的方法 - Google Patents

包含mgbg的口服递送药物以及治疗疾病的方法 Download PDF

Info

Publication number
CN102686222B
CN102686222B CN201080041853.XA CN201080041853A CN102686222B CN 102686222 B CN102686222 B CN 102686222B CN 201080041853 A CN201080041853 A CN 201080041853A CN 102686222 B CN102686222 B CN 102686222B
Authority
CN
China
Prior art keywords
group
polyamine
composition
mgbg
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080041853.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN102686222A (zh
Inventor
J·麦基尔恩
J·布利策
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pathologica LLC
Original Assignee
Pathologica LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pathologica LLC filed Critical Pathologica LLC
Priority to CN201510274080.4A priority Critical patent/CN104997762B/zh
Publication of CN102686222A publication Critical patent/CN102686222A/zh
Application granted granted Critical
Publication of CN102686222B publication Critical patent/CN102686222B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
CN201080041853.XA 2009-07-16 2010-07-16 包含mgbg的口服递送药物以及治疗疾病的方法 Expired - Fee Related CN102686222B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510274080.4A CN104997762B (zh) 2009-07-16 2010-07-16 包含mgbg的口服递送药物以及治疗疾病的方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22606009P 2009-07-16 2009-07-16
US61/226,060 2009-07-16
US29009509P 2009-12-24 2009-12-24
US61/290,095 2009-12-24
PCT/US2010/042253 WO2011009039A2 (en) 2009-07-16 2010-07-16 Pharmaceutical for oral delivery comprising mgbg and methods of treating disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510274080.4A Division CN104997762B (zh) 2009-07-16 2010-07-16 包含mgbg的口服递送药物以及治疗疾病的方法

Publications (2)

Publication Number Publication Date
CN102686222A CN102686222A (zh) 2012-09-19
CN102686222B true CN102686222B (zh) 2015-06-24

Family

ID=43450234

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201080041853.XA Expired - Fee Related CN102686222B (zh) 2009-07-16 2010-07-16 包含mgbg的口服递送药物以及治疗疾病的方法
CN201510274080.4A Expired - Fee Related CN104997762B (zh) 2009-07-16 2010-07-16 包含mgbg的口服递送药物以及治疗疾病的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510274080.4A Expired - Fee Related CN104997762B (zh) 2009-07-16 2010-07-16 包含mgbg的口服递送药物以及治疗疾病的方法

Country Status (11)

Country Link
US (4) US8258186B2 (https=)
EP (2) EP3473247A1 (https=)
JP (4) JP6112449B2 (https=)
CN (2) CN102686222B (https=)
AU (2) AU2010273277B2 (https=)
BR (1) BR112012000862A8 (https=)
CA (1) CA2768018C (https=)
DK (1) DK2453886T3 (https=)
ES (1) ES2715173T3 (https=)
NZ (3) NZ628513A (https=)
WO (1) WO2011009039A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2121586T3 (en) 2007-03-09 2017-06-19 Pathologica Llc MGBG FOR THE REGULATION OF OSTEOPONTIN AND THE TREATMENT OF MULTIPLE SCLEROSIS
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
JP6112449B2 (ja) 2009-07-16 2017-04-12 パソロジカ エルエルシー Ｍｇｂｇを含む経口送達用の医薬品および疾患を処置する方法
NO2665471T3 (https=) 2011-01-19 2018-05-26
WO2013083813A2 (en) * 2011-12-07 2013-06-13 Universität Zürich Modulators of spermine/spermidine n'-acetyltransferase (ssat) and ssat associated proteins for use in prevention or treatment of rheumatoid arthritis
WO2014062552A1 (en) * 2012-10-15 2014-04-24 Nestec Sa Methods for maintaining eye health and ameliorating opthalmic maladies in animals
CN109432073A (zh) * 2013-01-08 2019-03-08 帕萨罗杰卡有限公司 Mgbg在制备治疗或预防进行性ms及其进展的药物中的用途
HUE052620T2 (hu) 2016-03-25 2021-05-28 Aminex Therapeutics Inc Biológiailag hozzáférhetõ poliaminok
WO2018027149A1 (en) * 2016-08-04 2018-02-08 University Of Miami Methods of treating alport syndrome
JP6840386B2 (ja) * 2017-04-26 2021-03-10 学校法人 関西大学 細胞足場材料製造用組成物ならびに細胞足場材料およびその製造方法
EP4126017A4 (en) * 2020-04-03 2024-05-22 Baylor College of Medicine Tnf-alpha signaling triggers tumor-promoting inflammation that can be targeted to therapy
JP2023545674A (ja) 2020-09-30 2023-10-31 アミネックス セラピューティクス， インコーポレイテッド ポリアミン輸送阻害剤およびｄｆｍｏの配合原薬
WO2024155777A2 (en) * 2023-01-19 2024-07-25 Dare Bioscience, Inc. Compositions and techniques for treatment of polycystic ovarian syndrome (pcos) and endometriosis
WO2024155775A2 (en) * 2023-01-19 2024-07-25 Dare Bioscience, Inc. Compositions and techniques for treatment of polycystic ovarian syndrome (pcos) and endometriosis
WO2024158951A2 (en) * 2023-01-25 2024-08-02 Dare Bioscience, Inc. Compositions and methods for treating dysmenorrhea

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614557A (en) * 1977-07-11 1997-03-25 Marion Merrell Et Compagnie C/O Merrell Pharmaceuticals Inc. Method of controlling tumor growth rate
US20050159493A1 (en) * 1997-10-27 2005-07-21 Mcgrath Michael S. Methods for modulating macrophage proliferation using polyamine analogs
US20070078187A1 (en) * 2005-09-23 2007-04-05 Pathologica, Llc. Methods for treating viral infections using polyamine analogs
US20080262092A1 (en) * 2007-03-09 2008-10-23 Pathologica Llc. Regulation of osteopontin
WO2009018368A1 (en) * 2007-07-30 2009-02-05 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Combination treatment of nmda (n-methyl-d-aspartate)-enhancer, glycine transporter inhibitor, d-amino acid oxidase inhibitor (daaoi) for neuropsychiatric disorders

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201788A (en) * 1976-10-20 1980-05-06 University Patents, Inc. Process for alleviating proliferative skin diseases
US5639600A (en) 1994-08-05 1997-06-17 The Regents Of The University Of California Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement
US5580715A (en) 1994-08-05 1996-12-03 The Regents Of The University Of California Diagnosis of cancer having clonal macrophage involvement
US5698563A (en) 1995-01-13 1997-12-16 Alteon Inc. Bis- hydrazones!
CA2264745C (en) 1996-09-13 2003-11-11 University Of Florida Research Foundation, Inc. Method of inhibiting biosynthesis of eif5a
AR009380A1 (es) 1996-10-21 2000-04-12 Sumitomo Chemical Co Proceso de preparacion de un derivado de piridazin-3-ona, util como herbicida, acido carboxilico de utilizacion en el mismo, sal de este ultimo y proceso para preparar dicho acido carboxilico
US6083496A (en) 1996-10-22 2000-07-04 Universite Laval Polyamine transport inhibitors
JP4044728B2 (ja) 1997-07-15 2008-02-06 メディクエスト セラピューティックス インク 治療および診断薬剤としての新規なポリアミンアナログ
US5889061A (en) 1997-10-15 1999-03-30 Wisconsin Alumni Research Foundation Conformationally restricted polyamines
US8198334B2 (en) 1997-10-27 2012-06-12 Pathologica Llc Methods for modulating macrophage proliferation in ocular disease using polyamine analogs
US6169115B1 (en) * 1998-05-22 2001-01-02 Rima Kaddurah-Daouk Use of aminoguanidine analogs for the treatment of diseases of the nervous system
US7312244B2 (en) 1999-04-30 2007-12-25 Cellgate, Inc. Polyamine analog-amino acid conjugates useful as anticancer agents
DE60029944T2 (de) 1999-04-30 2007-04-05 Cellgate, Inc., Redwood City Polyamine und ihre therapeutische verwendung
US6544541B1 (en) 1999-06-02 2003-04-08 Cardiovascular Solutions, Inc. Devices and compounds for treating arterial restenosis
US7754765B2 (en) 2000-12-01 2010-07-13 Radical Vision Therapeutics Inc Copper chelators for treating ocular inflammation
WO2002053519A2 (en) 2001-01-08 2002-07-11 Mediquest Therapeutics, Inc. Hydrophobic polyamine analogs and methods for their use
WO2003013245A1 (en) 2001-08-07 2003-02-20 Wisconsin Alumni Research Foundation Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy
WO2003016491A2 (en) 2001-08-15 2003-02-27 The Regents Of The University Of California Retrovirus isolated from mantle histiocytes in mantle cell lymphoma
JP2005510524A (ja) 2001-11-16 2005-04-21 アルス・セラピー・デベロツプメント・フアンデーシヨン・インコーポレーテツド ポリアミン経路の調節による神経変性障害の治療
US7622117B2 (en) 2002-04-17 2009-11-24 Dynamis Therapeutics, Inc. 3-deoxyglucosone and skin
EP1613263A4 (en) 2003-01-31 2007-11-28 Pathologica Llc MONITORING AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
US20050025825A1 (en) 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
WO2005041988A1 (en) 2003-10-22 2005-05-12 University Of Florida Method and composition for pain amelioration
AU2004319105A1 (en) 2004-03-29 2005-11-10 Mediquest Therapeutics, Inc. Polyamine analogs that activate antizyme frameshifting
WO2005107801A2 (en) 2004-04-29 2005-11-17 The Regents Of The University Of Colorado Systems and methods for treating human inflammatory and proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors and/or ucp and/or fas antibodies
CA2617150C (en) 2005-07-29 2016-06-14 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Use of chk2 kinase inhibitors for cancer treatment
WO2007040535A1 (en) 2005-10-03 2007-04-12 Cellgate, Inc. Use of polyamine analogs for treatment and prevention of intestinal polyps
US20080026209A1 (en) * 2006-07-28 2008-01-31 Sunitha Grandhee Automotive panel having polyurethane primer
US20110091418A1 (en) 2006-09-25 2011-04-21 Pathlogica, LLC Methods for treating viral infections using polyamine analogs
WO2008112251A1 (en) 2007-03-14 2008-09-18 Progen Pharmaceuticals, Inc. Cyclopropyl-containing polyamine analogs as disease therapies
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
JP6112449B2 (ja) 2009-07-16 2017-04-12 パソロジカ エルエルシー Ｍｇｂｇを含む経口送達用の医薬品および疾患を処置する方法
EP2283830A1 (en) 2009-07-23 2011-02-16 Actogenix N.V. Aqueous enteric capsule coating
NO2665471T3 (https=) 2011-01-19 2018-05-26
CN109432073A (zh) 2013-01-08 2019-03-08 帕萨罗杰卡有限公司 Mgbg在制备治疗或预防进行性ms及其进展的药物中的用途

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614557A (en) * 1977-07-11 1997-03-25 Marion Merrell Et Compagnie C/O Merrell Pharmaceuticals Inc. Method of controlling tumor growth rate
US20050159493A1 (en) * 1997-10-27 2005-07-21 Mcgrath Michael S. Methods for modulating macrophage proliferation using polyamine analogs
US20070078187A1 (en) * 2005-09-23 2007-04-05 Pathologica, Llc. Methods for treating viral infections using polyamine analogs
CN101300004A (zh) * 2005-09-23 2008-11-05 帕瑟洛吉卡有限公司 使用多胺类似物治疗病毒感染的方法
US20080262092A1 (en) * 2007-03-09 2008-10-23 Pathologica Llc. Regulation of osteopontin
WO2009018368A1 (en) * 2007-07-30 2009-02-05 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Combination treatment of nmda (n-methyl-d-aspartate)-enhancer, glycine transporter inhibitor, d-amino acid oxidase inhibitor (daaoi) for neuropsychiatric disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
pharmacology of methylglyoxal-bis-(guanylhydrazone)(CH3-G);E. Mihich, et al.;《cancer research》;19620930;第22卷(第9期);962-972 *
the distribution, excretion, and metabolism of methylglyoxal-bis-guanylhydrazone-C14;Vincent T. Oliverio, et al;《Journal of pharmacology and experimental therapeutics》;19630831;第141卷(第2期);149-156 *

Also Published As

Publication number Publication date
JP6112449B2 (ja) 2017-04-12
CA2768018C (en) 2019-08-27
NZ715686A (en) 2017-08-25
ES2715173T3 (es) 2019-06-03
JP2018127460A (ja) 2018-08-16
AU2010273277B2 (en) 2016-12-22
US8258186B2 (en) 2012-09-04
EP2453886B1 (en) 2018-12-12
AU2010273277A1 (en) 2012-02-02
AU2016266049B2 (en) 2018-10-18
CN104997762A (zh) 2015-10-28
BR112012000862A8 (pt) 2018-01-09
NZ628513A (en) 2016-01-29
WO2011009039A3 (en) 2011-06-16
EP3473247A1 (en) 2019-04-24
CN102686222A (zh) 2012-09-19
DK2453886T3 (en) 2019-03-25
EP2453886A2 (en) 2012-05-23
JP2020063258A (ja) 2020-04-23
EP2453886A4 (en) 2012-12-05
US8609734B2 (en) 2013-12-17
JP2012533565A (ja) 2012-12-27
CA2768018A1 (en) 2011-01-20
WO2011009039A2 (en) 2011-01-20
JP6883930B2 (ja) 2021-06-09
BR112012000862A2 (pt) 2017-10-31
AU2016266049A1 (en) 2016-12-22
JP2016065045A (ja) 2016-04-28
NZ597488A (en) 2014-10-31
US20120289604A1 (en) 2012-11-15
US20170290788A1 (en) 2017-10-12
CN104997762B (zh) 2019-03-08
US20110112199A1 (en) 2011-05-12
US20140051765A1 (en) 2014-02-20
US9616035B2 (en) 2017-04-11
HK1176548A1 (en) 2013-08-02

Similar Documents

Publication Publication Date Title
CN102686222B (zh) 包含mgbg的口服递送药物以及治疗疾病的方法
AU2018247351B2 (en) Methods and compositions for treatment of demyelinating diseases
HK1176548B (en) Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
HK40007774A (en) Composition for oral delivery comprising mgbg for use in treating multiple sclerosis
HK1262206A1 (en) Use of mgbg for manufacturing a medicament for the treatment or prevention of progressive ms and its progression
HK40055723A (en) Mitoguazone for preventing the relapse or the progression of multiple sclerosis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1176548

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1176548

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150624